Rating Rationale
August 10, 2023 | Mumbai
Mangalam Drugs and Organics Limited
Ratings reaffirmed at 'CRISIL BBB-/Stable/CRISIL A3'; rated amount enhanced for Bank Debt
 
Rating Action
Total Bank Loan Facilities RatedRs.115 Crore (Enhanced from Rs.32 Crore)
Long Term RatingCRISIL BBB-/Stable (Reaffirmed)
Short Term RatingCRISIL A3 (Reaffirmed)
Note: None of the Directors on CRISIL Ratings Limited’s Board are members of rating committee and thus do not participate in discussion or assignment of any ratings. The Board of Directors also does not discuss any ratings at its meetings.
1 crore = 10 million
Refer to Annexure for Details of Instruments & Bank Facilities

Detailed Rationale

CRISIL Ratings has reaffirmed its CRISIL BBB-/Stable/CRISIL A3 ratings to the bank loan facilities of Mangalam Drugs and Organics Limited (MDOL).

 

On August 03, 2023, CRISIL Ratings had earlier assigned its CRISIL BBB-/Stable/CRISIL A3 ratings to the bank facilities of MDOL.

 

The ratings reflects MDOL's established market position in the Anti-Malarial Active Pharmaceutical Ingredients (API) segment supported by extensive experience of promoters and its healthy relationship with leading formulators across multiple geographies. The rating also factors in above average financial risk profile. These strengths are partially offset by susceptibility to volatility in raw material, demand risk and working capital intensive nature of operations.

Key Rating Drivers & Detailed Description

Strengths:

  • Established market position in the Anti-Malarial API segment supported by extensive experience of promoters: MDOL is among the few companies which is World Health Organisation (WHO) approved and has tied up with the William J Clinton foundation (Clinton Foundation) and other Non Governmental Organisation (NGO) and Not for Profit Organisations (NPO) for manufacture of anti-malarial drugs. These APIs are among the most widely prescribed combination therapies that have been recommended by the WHO as the first line of treatment for malaria globally. Besides anti-malarial segment, the company is also present in various segments such as anti-inflammatory, anti-hypertensive, anti-retroviral segment and anti-convulsant agent. Further, it also benefits from the promoters' experience of over four decades, their strong understanding of market dynamics, and healthy relations with customers and suppliers.

 

  • Moderate financial profile: Financial risk profile is marked by strong networth of Rs 151.9 crores as on March 31, 2023. Capital structure is healthy backed by moderate reliance on external funds yielding gearing estimated at 0.75 times and total outside liabilities to adjusted tangible networth (TOL/ANW) of 1.75 times as on 31st March 2023. The interest coverage and net cash accrual to total debt (NCATD) ratio are estimated at 2 times and 0.12 times for fiscal 2023. MDOL capital structure and debt protection measures are expected to further improve over the medium term on account of higher accretions to reserves.

 

Weaknesses:

  • Intense competition and demand risk: The bulk drugs industry is highly competitive due to presence of numerous domestic as well as global players, which constrains revenue growth and exerts pricing pressure on individual entities. The scale of operation is also susceptible to order flows from WHO along with other agencies and NGO’s, any funding constrains, or unfavorable policy decision can impact order flow and revenue growth. This can be seen from scale of operations declining from Rs 450 crore for fiscal 2022 to Rs 370 crore for fiscal 2023 on account of lower tenders floated. With unexecuted orders in hand, scale is expected to improve and will remain monitorable over medium term.

 

  • Susceptibility to volatility in raw material: MDOL's earnings before interest, taxes, depreciation and ammortisation (EBITDA) are heavily reliant on the prices of its main antimalarial raw material- Artemisinin. This can be seen from fluctuating operating margins in fiscal 2023 majorly on account of volatile raw material prices of Artemisinin. Operating margins have been on a declining trend from 15.1% for fiscal 2021 to around 7% for fiscal 2023. With raw material prices settling, operating margins are expected to improve which would remain key sensitivity factor.

 

  • Working capital intensive operations: Gross current assets (GCA) were estimated at around 200 days as on March 31, 2023 driven by debtors and inventory of around 72 & 145 days respectively. It is required to extend long credit period (60-90 days) in line with the industry standards. Inventory is higher as of March 2023 due to loss of sale due to lower demand; however, inventory is likely to remain at around 80-90 days over the medium term.

Liquidity: Adequate

Net cash accruals are expected to be around Rs 20 crore per fiscal over the medium term against debt obligation of around Rs 5-6 crore per fiscal. Bank limits were on average utilised at 90% over the past 12 months ended in May 2023. The company has cash and cash equivalent of Rs 2.68 crores (Encumbered & Unencumbered) as on March 31,2023. There is no significant debt funded capex planned over medium term.

Outlook: Stable

CRISIL Ratings believe MDOL will continue to benefit from the extensive experience of its promoter, and established relationships with clients.

Rating Sensitivity factors

Upward factors:

  • Improvement in scale of operations and operating margin leading net cash accruals of above Rs 20 crore.
  • Improvement in working capital cycle and improved debt protection metrics strengthens the overall financial risk profile and liquidity

 

Downward factors:

  • Decline in revenue or profitability weakens net cash accruals to below Rs.10 crore
  • Stretch in working capital cycle or large debt funded capex weakens the financial risk profile, especially debt protection metrics and liquidity

About the Company

MDOL (formerly, Advent Pharma Pvt Ltd), promoted by the Mumbai (Maharashtra)-based Dhoot family, was set up in 1972 as part of the Mangalam group. The company was reconstituted as a public limited company in 2001. MDOL manufactures bulk drugs, and organic and inorganic chemicals. MDOL is among the few companies which are World Health Organization (WHO)-approved Indian companies to be associated with the William J Clinton Foundation (Clinton Foundation) for manufacture of anti-malarial drugs; the company supplies artemisinin-based bulk drugs to pharmaceutical companies, for the manufacture of anti-malarial formulations.

Key Financial Indicators

As on / for the period ended March 31

 

2023

2022

Operating income

Rs crore

372.25

447.73

Reported profit after tax

Rs crore

1.2

19.66

PAT margins

%

0.3

4.4

Adjusted Debt/Adjusted Net worth

Times

0.75

0.76

Interest coverage

Times

2.0

4.4

Any other information: Not applicable

Note on complexity levels of the rated instrument:
CRISIL Ratings` complexity levels are assigned to various types of financial instruments and are included (where applicable) in the 'Annexure - Details of Instrument' in this Rating Rationale.

CRISIL Ratings will disclose complexity level for all securities - including those that are yet to be placed - based on available information. The complexity level for instruments may be updated, where required, in the rating rationale published subsequent to the issuance of the instrument when details on such features are available.

For more details on the CRISIL Ratings` complexity levels please visit www.crisilratings.com. Users may also call the Customer Service Helpdesk with queries on specific instruments.

Annexure - Details of Instrument(s)

ISIN Name of the
instrument
Date of
Allotment
Coupon
Rate (%)
Maturity
Date
Issue size
(Rs. Crore)
Complexity
Level
Rating assigned
with outlook
NA Cash Credit NA NA NA 60 NA CRISIL BBB-/Stable
NA Letter of Credit NA NA NA 20 NA CRISIL A3
NA Term Loan NA NA Mar-26 9.25 NA CRISIL BBB-/Stable
NA Working Capital Term Loan NA NA Mar-26 11.75 NA CRISIL BBB-/Stable
NA Foreign Exchange Forward NA NA NA 1.5 NA CRISIL A3
NA Bank Guarantee NA NA NA 2.5 NA CRISIL A3
NA Proposed Long Term Bank Loan Facility NA NA NA 10 NA CRISIL BBB-/Stable
Annexure - Rating History for last 3 Years
  Current 2023 (History) 2022  2021  2020  Start of 2020
Instrument Type Outstanding Amount Rating Date Rating Date Rating Date Rating Date Rating Rating
Fund Based Facilities LT/ST 92.5 CRISIL BBB-/Stable / CRISIL A3 03-08-23 CRISIL BBB-/Stable   --   --   -- Withdrawn
      --   --   --   --   -- Withdrawn
Non-Fund Based Facilities ST 22.5 CRISIL A3 03-08-23 CRISIL A3   --   --   -- Withdrawn
All amounts are in Rs.Cr.
Annexure - Details of Bank Lenders & Facilities
Facility Amount (Rs.Crore) Name of Lender Rating
Bank Guarantee 0.3 State Bank of India CRISIL A3
Bank Guarantee 1.5 State Bank of India CRISIL A3
Bank Guarantee 0.7 Bank of Baroda CRISIL A3
Cash Credit 30 State Bank of India CRISIL BBB-/Stable
Cash Credit 19 Bank of Baroda CRISIL BBB-/Stable
Cash Credit 11 Bank of Maharashtra CRISIL BBB-/Stable
Foreign Exchange Forward 0.5 State Bank of India CRISIL A3
Foreign Exchange Forward 1 Bank of Baroda CRISIL A3
Letter of Credit 7.5 Bank of Baroda CRISIL A3
Letter of Credit 12.5 Bank of Maharashtra CRISIL A3
Proposed Long Term Bank Loan Facility 10 Not Applicable CRISIL BBB-/Stable
Term Loan 9.25 State Bank of India CRISIL BBB-/Stable
Working Capital Term Loan 6.17 State Bank of India CRISIL BBB-/Stable
Working Capital Term Loan 4.15 Bank of Baroda CRISIL BBB-/Stable
Working Capital Term Loan 1.43 Bank of Maharashtra CRISIL BBB-/Stable
Criteria Details
Links to related criteria
CRISILs Approach to Financial Ratios
Rating criteria for manufaturing and service sector companies
CRISILs Bank Loan Ratings - process, scale and default recognition
Rating Criteria for the Pharmaceutical Industry
Understanding CRISILs Ratings and Rating Scales

Media Relations
Analytical Contacts
Customer Service Helpdesk

Aveek Datta
Media Relations
CRISIL Limited
M: +91 99204 93912
B: +91 22 3342 3000
AVEEK.DATTA@crisil.com

Prakruti Jani
Media Relations
CRISIL Limited
M: +91 98678 68976
B: +91 22 3342 3000
PRAKRUTI.JANI@crisil.com

Rutuja Gaikwad 
Media Relations
CRISIL Limited
B: +91 22 3342 3000
Rutuja.Gaikwad@ext-crisil.com


Jaya Mirpuri
Director
CRISIL Ratings Limited
B:+91 22 3342 3000
jaya.mirpuri@crisil.com


Rushabh Pramod Borkar
Associate Director
CRISIL Ratings Limited
D:+91 22 3342 3390
rushabh.borkar@crisil.com


Aditya Shah
Rating Analyst
CRISIL Ratings Limited
B:+91 22 3342 3000
Aditya.Shah@crisil.com
Timings: 10.00 am to 7.00 pm
Toll free Number:1800 267 1301

For a copy of Rationales / Rating Reports:
CRISILratingdesk@crisil.com
 
For Analytical queries:
ratingsinvestordesk@crisil.com


 

Note for Media:
This rating rationale is transmitted to you for the sole purpose of dissemination through your newspaper/magazine/agency. The rating rationale may be used by you in full or in part without changing the meaning or context thereof but with due credit to CRISIL Ratings. However, CRISIL Ratings alone has the sole right of distribution (whether directly or indirectly) of its rationales for consideration or otherwise through any media including websites and portals.


About CRISIL Ratings Limited (A subsidiary of CRISIL Limited, an S&P Global Company)

CRISIL Ratings pioneered the concept of credit rating in India in 1987. With a tradition of independence, analytical rigour and innovation, we set the standards in the credit rating business. We rate the entire range of debt instruments, such as bank loans, certificates of deposit, commercial paper, non-convertible/convertible/partially convertible bonds and debentures, perpetual bonds, bank hybrid capital instruments, asset-backed and mortgage-backed securities, partial guarantees and other structured debt instruments. We have rated over 33,000 large and mid-scale corporates and financial institutions. We have also instituted several innovations in India in the rating business, including ratings for municipal bonds, partially guaranteed instruments and infrastructure investment trusts (InvITs).
 
CRISIL Ratings Limited ('CRISIL Ratings') is a wholly-owned subsidiary of CRISIL Limited ('CRISIL'). CRISIL Ratings Limited is registered in India as a credit rating agency with the Securities and Exchange Board of India ("SEBI").
 
For more information, visit www.crisilratings.com 

 



About CRISIL Limited

CRISIL is a leading, agile and innovative global analytics company driven by its mission of making markets function better. 

It is India’s foremost provider of ratings, data, research, analytics and solutions with a strong track record of growth, culture of innovation, and global footprint.

It has delivered independent opinions, actionable insights, and efficient solutions to over 100,000 customers through businesses that operate from India, the US, the UK, Argentina, Poland, China, Hong Kong and Singapore.

It is majority owned by S&P Global Inc, a leading provider of transparent and independent ratings, benchmarks, analytics and data to the capital and commodity markets worldwide.

For more information, visit www.crisil.com

Connect with us: TWITTER | LINKEDIN | YOUTUBE | FACEBOOK


CRISIL PRIVACY NOTICE
 
CRISIL respects your privacy. We may use your contact information, such as your name, address and email id to fulfil your request and service your account and to provide you with additional information from CRISIL. For further information on CRISIL's privacy policy please visit www.crisil.com.



DISCLAIMER

This disclaimer is part of and applies to each credit rating report and/or credit rating rationale ('report') that is provided by CRISIL Ratings Limited ('CRISIL Ratings'). To avoid doubt, the term 'report' includes the information, ratings and other content forming part of the report. The report is intended for the jurisdiction of India only. This report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the report is to be construed as CRISIL Ratings providing or intending to provide any services in jurisdictions where CRISIL Ratings does not have the necessary licenses and/or registration to carry out its business activities referred to above. Access or use of this report does not create a client relationship between CRISIL Ratings and the user.

We are not aware that any user intends to rely on the report or of the manner in which a user intends to use the report. In preparing our report we have not taken into consideration the objectives or particular needs of any particular user. It is made abundantly clear that the report is not intended to and does not constitute an investment advice. The report is not an offer to sell or an offer to purchase or subscribe for any investment in any securities, instruments, facilities or solicitation of any kind to enter into any deal or transaction with the entity to which the report pertains. The report should not be the sole or primary basis for any investment decision within the meaning of any law or regulation (including the laws and regulations applicable in the US).

Ratings from CRISIL Ratings are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold or sell any securities/instruments or to make any investment decisions. Any opinions expressed here are in good faith, are subject to change without notice, and are only current as of the stated date of their issue. CRISIL Ratings assumes no obligation to update its opinions following publication in any form or format although CRISIL Ratings may disseminate its opinions and analysis. The rating contained in the report is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment or other business decisions. The recipients of the report should rely on their own judgment and take their own professional advice before acting on the report in any way. CRISIL Ratings or its associates may have other commercial transactions with the entity to which the report pertains.

Neither CRISIL Ratings nor its affiliates, third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively, 'CRISIL Ratings Parties') guarantee the accuracy, completeness or adequacy of the report, and no CRISIL Ratings Party shall have any liability for any errors, omissions or interruptions therein, regardless of the cause, or for the results obtained from the use of any part of the report. EACH CRISIL RATINGS PARTY DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING BUT NOT LIMITED TO ANY WARRANTIES OF MERCHANTABILITY, SUITABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall any CRISIL Ratings Party be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the report even if advised of the possibility of such damages.

CRISIL Ratings may receive compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors. Public ratings and analysis by CRISIL Ratings, as are required to be disclosed under the regulations of the Securities and Exchange Board of India (and other applicable regulations, if any), are made available on its website, www.crisilratings.com (free of charge). Reports with more detail and additional information may be available for subscription at a fee - more details about ratings by CRISIL Ratings are available here: www.crisilratings.com.

CRISIL Ratings and its affiliates do not act as a fiduciary. While CRISIL Ratings has obtained information from sources it believes to be reliable, CRISIL Ratings does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives and/or relies on in its reports. CRISIL Ratings has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process. CRISIL Ratings has in place a ratings code of conduct and policies for managing conflict of interest. For details please refer to:
https://www.crisil.com/en/home/our-businesses/ratings/regulatory-disclosures/highlighted-policies.html.

Rating criteria by CRISIL Ratings are generally available without charge to the public on the CRISIL Ratings public website, www.crisilratings.com. For latest rating information on any instrument of any company rated by CRISIL Ratings, you may contact the CRISIL Ratings desk at crisilratingdesk@crisil.com, or at (0091) 1800 267 1301.

This report should not be reproduced or redistributed to any other person or in any form without prior written consent from CRISIL Ratings.

All rights reserved @ CRISIL Ratings Limited. CRISIL Ratings is a wholly owned subsidiary of CRISIL Limited.

 

 

CRISIL Ratings uses the prefix 'PP-MLD' for the ratings of principal-protected market-linked debentures (PPMLD) with effect from November 1, 2011, to comply with the SEBI circular, "Guidelines for Issue and Listing of Structured Products/Market Linked Debentures". The revision in rating symbols for PPMLDs should not be construed as a change in the rating of the subject instrument. For details on CRISIL Ratings' use of 'PP-MLD' please refer to the notes to Rating scale for Debt Instruments and Structured Finance Instruments at the following link: https://www.crisil.com/en/home/our-businesses/ratings/credit-ratings-scale.html